Payment overview · 2025
General Payments
$417.80
11 reported records · 7 companies
Healthcare provider profile · identity verified
Robert A Midence, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Geriatric Medicine · SEBRING, FL · NPI 1578581112
Verified facts
What the public records show
CMS Open Payments records show Robert A Midence, MD received $417.80 in general payments during 2025 across 11 reported records.
Lilly USA, LLC accounted for 39.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 11 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Mounjaro, Ozempic, Rybelsus.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 28 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 69 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 83 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 63 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 153 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $165.84 | 39.7% | 3 | 2025 |
| INTUITIVE SURGICAL, INC. | Unresolved — no canonical attribution shown | $103.23 | 24.7% | 1 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $57.43 | 13.8% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.39 | 7.0% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $27.33 | 6.5% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $19.54 | 4.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.04 | 3.6% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $417.80 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $165.84 | 3 | 2025 |
Source payment records
|
|||||
| Da Vinci Surgical System Normalized: da vinci surgical system |
Device | INTUITIVE SURGICAL, INC. | $103.23 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $57.43 | 3 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $29.39 | 1 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $27.41 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $27.33 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $27.33 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $19.54 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 153 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 83 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 63 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
28 | suppressed by CMS |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
69 | 19 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
83 | 20 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
63 | 11 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
153 | 41 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
15 | 15 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 832 | 228 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 820 | 245 |
| Amlodipine Besylate | Amlodipine Besylate | 754 | 211 |
| Levothyroxine Sodium | Levothyroxine Sodium | 722 | 188 |
| Omeprazole | Omeprazole | 490 | 139 |
| Losartan Potassium | Losartan Potassium | 393 | 108 |
| Metformin Hcl | Metformin Hcl | 372 | 108 |
| Gabapentin | Gabapentin | 361 | 117 |
| Lisinopril | Lisinopril | 334 | 103 |
| Metoprolol Tartrate | Metoprolol Tartrate | 311 | 89 |
| Pantoprazole Sodium | Pantoprazole Sodium | 287 | 93 |
| Tamsulosin Hcl | Tamsulosin Hcl | 264 | 75 |
| Simvastatin | Simvastatin | 259 | 74 |
| Sertraline Hcl | Sertraline Hcl | 251 | 71 |
| Metoprolol Succinate | Metoprolol Succinate | 235 | 70 |
| Carvedilol | Carvedilol | 230 | 69 |
| Clopidogrel | Clopidogrel Bisulfate | 227 | 68 |
| Metformin Hcl Er | Metformin Hcl | 223 | 67 |
| Alprazolam | Alprazolam | 197 | 48 |
| Tramadol Hcl | Tramadol Hcl | 197 | 42 |
| Furosemide | Furosemide | 196 | 66 |
| Montelukast Sodium | Montelukast Sodium | 190 | 50 |
| Glimepiride | Glimepiride | 186 | 51 |
| Hydrochlorothiazide | Hydrochlorothiazide | 171 | 51 |
| Trazodone Hcl | Trazodone Hcl | 160 | 45 |
| Eliquis | Apixaban | 153 | 41 |
| Potassium Chloride | Potassium Chloride | 139 | 44 |
| Atenolol | Atenolol | 133 | 34 |
| Irbesartan | Irbesartan | 124 | 31 |
| Allopurinol | Allopurinol | 120 | 36 |
| Duloxetine Hcl | Duloxetine Hcl | 119 | 35 |
| Lorazepam | Lorazepam | 119 | 34 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 117 | 37 |
| Meloxicam | Meloxicam | 109 | 37 |
| Ezetimibe | Ezetimibe | 104 | 36 |
| Doxazosin Mesylate | Doxazosin Mesylate | 99 | 28 |
| Azithromycin | Azithromycin | 97 | 87 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 96 | 25 |
| Escitalopram Oxalate | Escitalopram Oxalate | 94 | 29 |
| Methylprednisolone | Methylprednisolone | 92 | 80 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 91 | 49 |
| Finasteride | Finasteride | 89 | 24 |
| Famotidine | Famotidine | 88 | 32 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 86 | 27 |
| Pravastatin Sodium | Pravastatin Sodium | 86 | 25 |
| Donepezil Hcl | Donepezil Hcl | 84 | 25 |
| Mounjaro | Tirzepatide | 83 | 20 |
| Diclofenac Sodium | Diclofenac Sodium | 81 | 44 |
| Bumetanide | Bumetanide | 76 | 21 |
| Nitrofurantoin | Nitrofurantoin Macrocrystal | 76 | 46 |
| Fluticasone Propionate | Fluticasone Propionate | 75 | 27 |
| Ipratropium Bromide | Ipratropium Bromide | 74 | 33 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 72 | 13 |
| Mirtazapine | Mirtazapine | 72 | 22 |
| Benazepril Hcl | Benazepril Hcl | 71 | 19 |
| Jardiance | Empagliflozin | 69 | 19 |
| Ibandronate Sodium | Ibandronate Sodium | 67 | 23 |
| Spironolactone | Spironolactone | 66 | 19 |
| Celecoxib | Celecoxib | 65 | 20 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 63 | 17 |
| Ozempic | Semaglutide | 63 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 61 | 15 |
| Synthroid | Levothyroxine Sodium | 59 | 13 |
| Cefuroxime | Cefuroxime Axetil | 53 | 46 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | 15 |
| Glipizide | Glipizide | 52 | 16 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 52 | 17 |
| Januvia | Sitagliptin Phosphate | 52 | 14 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 17 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 46 | 16 |
| Fenofibrate | Fenofibrate | 44 | 13 |
| Valsartan | Valsartan | 43 | 12 |
| Fluoxetine Hcl | Fluoxetine Hcl | 42 | 13 |
| Labetalol Hcl | Labetalol Hcl | 40 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 39 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 38 | 28 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 37 | 16 |
| Lovastatin | Lovastatin | 37 | suppressed |
| Clonazepam | Clonazepam | 35 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 35 | 12 |
| Symbicort | Budesonide/Formoterol Fumarate | 34 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 34 | suppressed |
| Pregabalin | Pregabalin | 33 | 14 |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Temazepam | Temazepam | 32 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 31 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 30 | suppressed |
| Ramipril | Ramipril | 30 | suppressed |
| Xarelto | Rivaroxaban | 29 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 28 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 28 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 27 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 27 | suppressed |
| Prednisone | Prednisone | 27 | 14 |
| Amoxicillin | Amoxicillin | 26 | 19 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 26 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 26 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 26 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 25 | 23 |
| Glipizide Er | Glipizide | 25 | suppressed |
| Rybelsus | Semaglutide | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 24 | 18 |
| Ondansetron Hcl | Ondansetron Hcl | 24 | 13 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 24 | 16 |
| Terazosin Hcl | Terazosin Hcl | 24 | suppressed |
| Baclofen | Baclofen | 23 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 23 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 23 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 23 | 11 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 22 | suppressed |
| Nitroglycerin | Nitroglycerin | 22 | 16 |
| Acyclovir | Acyclovir | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 21 | suppressed |
| Lansoprazole | Lansoprazole | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Tramadol Hcl Er | Tramadol Hcl | 21 | suppressed |
| Latanoprost | Latanoprost | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 19 | suppressed |
| Bupropion Hcl | Bupropion Hcl | 18 | suppressed |
| Dutasteride | Dutasteride | 18 | suppressed |
| Hydroxyzine Pamoate | Hydroxyzine Pamoate | 18 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 18 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 18 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 18 | suppressed |
| Estradiol | Estradiol | 17 | suppressed |
| Ibuprofen | Ibuprofen | 17 | suppressed |
| Bupropion Xl | Bupropion Hcl | 16 | suppressed |
| Gemfibrozil | Gemfibrozil | 16 | suppressed |
| Verapamil Er | Verapamil Hcl | 16 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 15 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 15 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 15 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 15 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 15 | 15 |
| Doxepin Hcl | Doxepin Hcl | 14 | suppressed |
| Levemir Flexpen | Insulin Detemir | 14 | suppressed |
| Nifedipine Er | Nifedipine | 14 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 14 | suppressed |
| Potassium Citrate Er | Potassium Citrate | 14 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 14 | suppressed |
| Primidone | Primidone | 14 | suppressed |
| Repatha Syringe | Evolocumab | 14 | suppressed |
| Trulicity | Dulaglutide | 14 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 13 | 12 |
| Clotrimazole | Clotrimazole | 13 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 13 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Methotrexate | Methotrexate Sodium | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Topiramate | Topiramate | 13 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 12 | suppressed |
| Cilostazol | Cilostazol | 12 | suppressed |
| Clonidine | Clonidine | 12 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 12 | 11 |
| Fluconazole | Fluconazole | 12 | 12 |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 12 | suppressed |
| Mupirocin | Mupirocin | 12 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 12 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Linzess | Linaclotide | 11 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $417.80 · 11 records | Lilly USA, LLC | AREXVY, Da Vinci Surgical System, ELIQUIS, Korlym, MOUNJARO, NURTEC ODT, Ozempic, Rybelsus, SHINGRIX, The Cologuard Plus Collection Kit, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error